CR11707A - Cristal de compuestos de bencimidazol - Google Patents

Cristal de compuestos de bencimidazol

Info

Publication number
CR11707A
CR11707A CR11707A CR11707A CR11707A CR 11707 A CR11707 A CR 11707A CR 11707 A CR11707 A CR 11707A CR 11707 A CR11707 A CR 11707A CR 11707 A CR11707 A CR 11707A
Authority
CR
Costa Rica
Prior art keywords
bencimidazol
composite crystal
methyl
crystal
trifluoroethoxy
Prior art date
Application number
CR11707A
Other languages
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40577894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11707(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR11707A publication Critical patent/CR11707A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee un cristal de (R)-2- [[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridinil]metil]sulfinil]-1H- bencimidazol que muestra un patron de analisis de difraccion de rayos X de polvo con picos caracteristicos en espacios interplanos.
CR11707A 2008-03-10 2010-09-30 Cristal de compuestos de bencimidazol CR11707A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008059342 2008-03-10

Publications (1)

Publication Number Publication Date
CR11707A true CR11707A (es) 2010-11-04

Family

ID=40577894

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11707A CR11707A (es) 2008-03-10 2010-09-30 Cristal de compuestos de bencimidazol

Country Status (30)

Country Link
US (1) US8222422B2 (es)
EP (1) EP2262790B1 (es)
JP (3) JP2011513202A (es)
KR (1) KR20100123758A (es)
CN (1) CN102026994B (es)
AR (1) AR070972A1 (es)
AU (1) AU2009224247B2 (es)
BR (1) BRPI0909651A2 (es)
CA (1) CA2671369C (es)
CL (1) CL2009000547A1 (es)
CO (1) CO6300956A2 (es)
CR (1) CR11707A (es)
DO (1) DOP2010000274A (es)
EA (1) EA017064B1 (es)
EC (1) ECSP10010531A (es)
ES (1) ES2638463T3 (es)
GE (1) GEP20125649B (es)
IL (1) IL207867A0 (es)
LT (1) LT2262790T (es)
MA (1) MA32215B1 (es)
MX (1) MX2010009641A (es)
MY (1) MY150833A (es)
NZ (1) NZ588379A (es)
PE (1) PE20091680A1 (es)
PT (1) PT2262790T (es)
TW (1) TWI447110B (es)
UA (1) UA103189C2 (es)
UY (1) UY31695A (es)
WO (1) WO2009113696A1 (es)
ZA (1) ZA201006754B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
CN102108077B (zh) * 2009-12-23 2013-09-25 江苏豪森医药集团有限公司 制备右兰索拉唑的方法
AU2011210328A1 (en) * 2010-01-29 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
CN104447695A (zh) * 2013-11-22 2015-03-25 广东东阳光药业有限公司 一种苯并咪唑化合物的水合物
SMT202100399T1 (it) 2015-06-08 2021-09-14 Hk Inno N Corp Utilizzo dei derivati del benzimidazolo episodi acidi notturni
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
CN106866631A (zh) * 2017-04-06 2017-06-20 山东裕欣药业有限公司 一种右旋兰索拉唑晶型及制备方法
CA3073957A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
DK3801526T3 (da) 2018-05-25 2024-03-25 Cardurion Pharmaceuticals Inc Monohydrate og krystallinske former af 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imidazo[1,5-a]pyrazin-8-on
JPWO2020013330A1 (ja) 2018-07-13 2021-06-24 協和発酵バイオ株式会社 ユーコミン酸の非溶媒和物結晶及びその製造方法
CN113376273B (zh) * 2021-06-02 2023-03-17 国药集团精方（安徽）药业股份有限公司 一种清心莲子饮hplc特征图谱的检测方法及该特征图谱的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (xx) 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
DK0987256T3 (da) * 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
AU742620B2 (en) 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
EP1056457A4 (en) 1998-01-30 2006-10-25 Sepracor Inc S-LANZOPRAZOL COMPOSITIONS AND METHODS
WO1999056698A2 (en) 1998-05-06 1999-11-11 Københavns Universitet Treatment of celiac disease
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
EP1897877B1 (en) * 2000-05-15 2014-09-24 Takeda Pharmaceutical Company Limited Crystalline forms of (R)-lanzoprazole
JP4327424B2 (ja) * 2000-05-15 2009-09-09 武田薬品工業株式会社 結晶の製造法
JP3374314B2 (ja) * 2000-05-15 2003-02-04 武田薬品工業株式会社 結晶の製造法
PL399787A1 (pl) 2000-12-01 2012-11-05 Takeda Pharmaceutical Company Ltd. Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie
JP4160293B2 (ja) * 2000-12-01 2008-10-01 武田薬品工業株式会社 結晶の製造法
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
CA2676477A1 (en) 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole

Also Published As

Publication number Publication date
MA32215B1 (fr) 2011-04-01
TW200938531A (en) 2009-09-16
NZ588379A (en) 2012-07-27
MY150833A (en) 2014-02-28
CL2009000547A1 (es) 2010-05-07
US20110046183A1 (en) 2011-02-24
AR070972A1 (es) 2010-05-19
LT2262790T (lt) 2017-08-25
WO2009113696A1 (en) 2009-09-17
EA017064B1 (ru) 2012-09-28
EP2262790B1 (en) 2017-06-07
GEP20125649B (en) 2012-09-25
AU2009224247A1 (en) 2009-09-17
ZA201006754B (en) 2011-11-30
US8222422B2 (en) 2012-07-17
JP2015163623A (ja) 2015-09-10
IL207867A0 (en) 2010-12-30
EA201071053A1 (ru) 2011-04-29
DOP2010000274A (es) 2010-09-30
EP2262790A1 (en) 2010-12-22
CN102026994B (zh) 2014-05-07
TWI447110B (zh) 2014-08-01
JP2011513202A (ja) 2011-04-28
PT2262790T (pt) 2017-07-18
ES2638463T3 (es) 2017-10-20
JP2014015477A (ja) 2014-01-30
UY31695A (es) 2009-11-10
KR20100123758A (ko) 2010-11-24
AU2009224247A2 (en) 2010-10-28
BRPI0909651A2 (pt) 2015-09-22
CA2671369C (en) 2011-05-10
UA103189C2 (ru) 2013-09-25
MX2010009641A (es) 2010-09-22
CA2671369A1 (en) 2009-09-10
CN102026994A (zh) 2011-04-20
AU2009224247B2 (en) 2013-12-12
PE20091680A1 (es) 2009-11-16
CO6300956A2 (es) 2011-07-21
ECSP10010531A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
CR11707A (es) Cristal de compuestos de bencimidazol
ATE430150T1 (de) 8-ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
EP2027583A4 (en) COMPACT NEUTRON SOURCE AND MODERATOR
PL2031126T3 (pl) Sposób i urządzenie ssące do wytwarzania papieru zabezpieczonego
EP2305458A4 (en) VENTILATION FILTER AND MANUFACTURING METHOD THEREFOR
EP2116372A4 (en) MULTILAYER POROUS MEMBRANE AND METHOD OF MANUFACTURING THEREOF
ATE490243T1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
EP2368544A4 (en) RASCH IN MOUTH DAMAGING TABLET AND METHOD FOR THEIR MANUFACTURE
EP2198327A4 (en) MODULAR FIBER CASSETTES AND METHOD FOR MANAGING GLASS FIBERS
EP2006700A4 (en) MAGNETIC SENSOR AND METHOD FOR THE PRODUCTION THEREOF
EP2004493A4 (en) SELF-WRAPPING FLEECE ACOUSTIC CASING AND METHOD FOR THE PRODUCTION THEREOF
EP1920338A4 (en) NETWORK SECURITY SYSTEMS AND METHODS
BRPI0920647A2 (pt) composto de piperidina e composição farmacêutica e respectivo uso e método de tratamento de doença gastrointestinal em mamífero
EP2036889A4 (en) SUBSTITUTED INDOLE AND PROCESS FOR THEIR PREPARATION AND USE
FR2940016B1 (fr) Gant impermeable et procede de fabrication de celui-ci
EP2100433A4 (en) Light conductor key plate and method for its production
ITVA20060006A1 (it) Tessuto non tessuto cattura-colori e metodo per la sua produzione
EP1841581A4 (en) COMPOSITE MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP1886289A4 (en) SYSTEMS AND METHODS FOR RECEIVING ORDERS
FI20055003A0 (fi) Järjestely ja menetelmä polttokennolaitteistossa
NO20055034D0 (no) Fremgangsmater for a analysere strukturen av et nettverk
ITBG20070005A1 (it) Gruppo per l'analisi di una superficie tridimensionale di un manufatto e macchina comprendente tale gruppo.
EP2117037A4 (en) INTERIOR LAYER INSULATION FILM, CONNECTING STRUCTURE AND MANUFACTURING METHOD THEREFOR
EP2184771A4 (en) FILM FOR ISOLATION BETWEEN LAYERS AND WIRING STRUCTURE AND MANUFACTURING METHOD THEREFOR
MX2011011177A (es) Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)
FA Abandonment or withdrawal (granting procedure)